{
    "guideline_identifier": "PIIS2059702923014369.txt",
    "cancer_focus": {
        "primary_cancer": "Not specified (applies to various cancers)",
        "related_syndrome_or_condition": "Chemotherapy-Induced Nausea and Vomiting (CINV), Radiotherapy-Induced Nausea and Vomiting (RINV)"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Chemotherapy: High risk (≥90% vomiting risk - e.g., cisplatin, AC combinations)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Non-AC HEC acute phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "4-drug regimen: 5-HT₃ RA + dexamethasone + NK₁ RA + olanzapine pre-chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                },
                {
                    "clinical_context": "Non-AC HEC delayed phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Dexamethasone + olanzapine (days 2–4)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                },
                {
                    "clinical_context": "AC-based HEC acute phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "4-drug regimen: 5-HT₃ RA + dexamethasone + NK₁ RA + olanzapine",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                },
                {
                    "clinical_context": "AC-based HEC delayed phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Olanzapine alone (days 2–4); 10 mg/day (5 mg if sedation concern)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        },
        {
            "staging_criteria": "Chemotherapy: Moderate risk (30–90% vomiting risk - e.g., carboplatin AUC≥5, oxaliplatin)",
            "risk_group": "Moderate risk",
            "treatment_plans": [
                {
                    "clinical_context": "Carboplatin (AUC≥5) acute phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "3-drug regimen: 5-HT₃ RA + dexamethasone + NK₁ RA",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                },
                {
                    "clinical_context": "Carboplatin (AUC≥5) delayed phase",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "No routine prophylaxis",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                },
                {
                    "clinical_context": "Oxaliplatin acute phase (general)",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "2-drug regimen: 5-HT₃ RA (palonosetron preferred) + dexamethasone",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, C"
                },
                {
                    "clinical_context": "Oxaliplatin acute phase (women ≤50 years)",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Add NK₁ RA to 2-drug regimen",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "III, B"
                },
                {
                    "clinical_context": "Other MEC (e.g., ADCs)",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Manage as carboplatin AUC≥5",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, C"
                }
            ]
        },
        {
            "staging_criteria": "Chemotherapy: Low risk (10–30% vomiting risk)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "Low-risk chemotherapy",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Single agent (dexamethasone, 5-HT₃ RA, or dopamine RA)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        },
        {
            "staging_criteria": "Chemotherapy: Minimal risk (<10% vomiting risk)",
            "risk_group": "Minimal risk",
            "treatment_plans": [
                {
                    "clinical_context": "Minimal-risk chemotherapy",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "No routine prophylaxis",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV, D"
                }
            ]
        },
        {
            "staging_criteria": "Special Scenarios: High-dose chemotherapy (stem cell transplant)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Stem cell transplant conditioning",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "5-HT₃ RA + dexamethasone + NK₁ RA ± olanzapine",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                }
            ]
        },
        {
            "staging_criteria": "Special Scenarios: Multi-day cisplatin",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Multi-day cisplatin regimens",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "5-HT₃ RA (daily) + dexamethasone (days 1–post) + aprepitant + olanzapine",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I, A"
                }
            ]
        },
        {
            "staging_criteria": "Special Scenarios: Breakthrough CINV",
            "risk_group": "Not applicable",
            "treatment_plans": [
                {
                    "clinical_context": "Breakthrough CINV (any emetic risk)",
                    "recommendation_type": "Rescue",
                    "recommendation_content": "Olanzapine 10 mg/day × 3 days (if not used prophylactically)",
                    "treatment_line": "Breakthrough",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        },
        {
            "staging_criteria": "Radiotherapy: High risk (e.g., TBI, upper abdomen)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "RINV prophylaxis",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "5-HT₃ RA ± dexamethasone",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, A"
                }
            ]
        },
        {
            "staging_criteria": "Radiotherapy: Moderate risk (e.g., craniospinal, pelvis)",
            "risk_group": "Moderate risk",
            "treatment_plans": [
                {
                    "clinical_context": "RINV prophylaxis",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "5-HT₃ RA ± dexamethasone",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, A"
                }
            ]
        },
        {
            "staging_criteria": "Radiotherapy: Low risk (e.g., brain, head/neck, thorax)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "RINV management",
                    "recommendation_type": "Rescue",
                    "recommendation_content": "Rescue therapy only (dexamethasone, dopamine RA, or 5-HT₃ RA)",
                    "treatment_line": "Symptomatic",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV, B"
                }
            ]
        },
        {
            "staging_criteria": "Radiotherapy: Minimal risk (e.g., extremities, breast)",
            "risk_group": "Minimal risk",
            "treatment_plans": [
                {
                    "clinical_context": "RINV management",
                    "recommendation_type": "Rescue",
                    "recommendation_content": "Rescue therapy only (dexamethasone, dopamine RA, or 5-HT₃ RA)",
                    "treatment_line": "Symptomatic",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "IV, B"
                }
            ]
        },
        {
            "staging_criteria": "Special Scenarios: Concomitant weekly cisplatin + RT",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Chemoradiotherapy",
                    "recommendation_type": "Prophylaxis",
                    "recommendation_content": "Aprepitant/fosaprepitant + 5-HT₃ RA + dexamethasone",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II, B"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "No specific diagnostic or predictive biomarkers identified; risk stratification based solely on emetogenic potential of treatment regimens and patient factors"
    }
}